- Home page
- Investor Relations
- Press Releases
-
Information on Share Buyback 14-18 July 2025
-
Information on share buyback 7 – 11 July 2025
-
Information on share buyback
-
Share Liquidity Management - Annex 3F June 2025
-
GVS - Start of Share Buyback Plan
-
GVS - Change of Industry Classification
-
GVS_Share Liquidity Management_Annex 3F_May 2025
-
Notice of publication of the minutes of the Shareholders’ Meeting
-
Publication of the updated Articles of Association
-
GVS - Q1 2025 Consolidated Results Approval
-
Update to the 2025 Corporate Financial Calendar
-
GVS Shareholders' Meeting approves 2024 financial statements
-
GVS_Share Liquidity Management_Annex 3F_April 2025
-
Notice of publication of Shareholders' Meeting documentation
-
Disclosure of total amount of voting rights
-
Notice of publication of Shareholders' Meeting documentation and supplement to the Press Release iussed on March 24, 2025
-
GVS_Share Liquidity Management_Annex 3F_March 2025
-
FY 2024 Consolidated Results Approval
-
The Board of Directors convenes Shareholders' Meeting for 8 May 2025
-
GVS_Share Liquidity Management_Annex 3F_February 2025
-
GVS - Share Liquidity Management_Annex 3F - January 2025
-
GVS - 2025 Calendar of Corporate Financial Events
-
GVS - Closing of Haemonetics Whole Blood Acquisition
-
GVS - Share Liquidity Management_Annex 3F - December 2024
-
GVS - Publication Updated By-laws
-
GVS - Notice of change in share capital
-
GVS - Subscription of the capital increase reserved for subscription by GVS Group S.r.l.
-
GVS - Publication Minutes of BoD and Updated By-laws
-
GVS-Euro 230,000,000 Facility Agreement dated June 2022_agreement with the pool of banks
-
GVS - Share Liquidity Management_Annex 3F - November 2024
-
GVS - Haemonetics Whole Blood Acquisition
-
The Board of Directors approves the capital increase reserved for subscription by GVS Group S.r.l.
-
GVS - Notice of publication of the information document
-
GVS - 9M 2024 Consolidated Results Approval
-
GVS - Share Liquidity Management_Annex 3F - September 2024
-
GVS - Renewal of Share Management Programme to Support Stock Liquidity
-
GVS - H1 2024 Consolidated Results Approval
-
GVS: Share Liquidity Management_Annex 3F - August 2024
-
GVS - H1 2024 Preliminary Consolidated Results Approval
-
GVS Share Liquidity Management Program - Annex 3F July 2024
-
Board of Directors approves GVS Sustainability Plan 2024 - 2026
-
GVS introduces the new Elipse® full face mask, redefining performance in Respiratory Protection
-
Share Liquidity Management - Annex 3F June 2024
-
Share Liquidity Management - Annex 3F May 2024
-
Notice of publication of documentation
-
Publication of Articles of Association approved by the Shareholders' Meeting on 7 May 2024
-
GVS - Q1 2024 Consolidated Results Approval
-
GVS Shareholders' Meeting approves 2023 financial statements
-
Share Liquidity Management_Annex 3F April 2024
-
Press release ex art. 85-bis Consob Regulation
-
Notice publication of documentation
-
Notice publication of documentation 05.04.2024
-
New Hydrogen Diaphragm
-
Share Liquidity Management - Annex 3F March 2024
-
GVS - FY 2023 Consolidated Results Approval
-
GVS - The Board of Directors convenes shareholders' meeting for Tuesday 7 May 2024
-
Disclosure of total amount of voting rights
-
Communication ex art. 143 quater comma 5 Consob Regulation
-
Share Liquidity Management - Annex 3F February 2024
-
Share Liquidity Management - Annex 3F January 2024
-
Calendar of Corporate Financial Events 2024
-
Share Liquidity Management - Annex 3F December 2023
-
Share Liquidity Management - Annex 3F November 2023
-
Share Liquidity Management - Annex 3F October 2023
-
GVS - Consolidated 9M 2023 Results ApprovalPrice Sensitive
-
Share Liquidity management
-
Share Liquidity Management - Annex 3F September 2023
-
GVS - 2023-2025 Financial Targets ApprovalPrice Sensitive
-
GVS Starts a Share Management Programme to Support Stock Liquidity
-
Notice of Publication of Documentation
-
GVS - Consolidated H1 2023 Results ApprovalPrice Sensitive
-
Notice of publication of documentation
-
Publication of Article of association
-
GVS - Consolidated Q1 2023 Results Approval
-
GVS Shareholders' meeting approves 2022 Financial Statement and the renewal of corporate bodies. Alessandro Nasi appointed Chairman
-
The Board of Directors appoints Massimo Scagliarini as CEO and establishes Board Committees
-
GVS - Amendment of the 2023 Calendar of Corporate Financial Events
-
Press release pursuant to art. 85-bis Issuers Reg_ Notice on total amount of voting rights
-
Publication of the lists for the appointment of the Board of Directors and the Board of Statutory Auditors
-
Notice of publication 12th April 2023
-
GVS - Consolidated FY 2022 Results ApprovalPrice Sensitive
-
GVS - Board of Directors convenes Shareholders' Meeting for Wednesday, May 3rd, 2023Price Sensitive
-
GVS - Subordinated loan by the majority shareholder - amendment of financial covenantPrice Sensitive
-
2023 Calendar Of Corporate Financial Events
-
GVS_ Disclosure of total amount of voting rights
-
GVS loses PMI (SME) status
-
Agreement to amend and adjust the financial covenant (leverage ratio) and commitment of the Shareholder to provide a subordinated shareholder loan
-
GVS Board of Directors approved the consolidated results as at 30 September 2022Price Sensitive
-
Marco Pacini is the new Group CFO of GVSPrice Sensitive
-
Notice: Publication of Documentation
-
The GVS BoD approved the consolidated results as at 30 June 2022Price Sensitive
-
Haemotronic Acquisition closing
-
Notice of pubblication
-
GVS acquires 100% of the Italian Group Haemotronic, leader in the production of components in the medical and pharmaceutical industries for 212 million euroPrice Sensitive
-
GVS Acquisition of 100% of the Italian Group Haemotronic - Integration of the Press Release
-
GVS Haemotronic Acquisition Analyst Presentation
-
GVS Haemotronic's Acquisition - AUDIO
-
The GVS BoD approved the consolidated results as at 31 March 2022
-
GVS Shareholders' Meeting approves 2021 Financial Statements
-
Notice on total amount of voting rights
-
Notice pubblication of documentation
-
The GVS Board of Directors approved the 2021 consolidated results and the draft financial statements as at 31 December 2021Price Sensitive
-
The Board of Directors convenes the shareholders' meeting for Thursday 28 April 2022
-
Acquisition of Shanghai Transfusion Technology Co. Ltd. completed a strategic opportunity for GVS to fully enter the Chinese healthcare market
-
Share buyback informationPrice Sensitive
-
Conclusion of the first part of the treasury shares purchase programPrice Sensitive
-
Share buyback information
-
Share buyback information
-
2022 Corporate Events Calendar
-
3F Buyback Dicember 2021
-
Share buyback information
-
GVS Acquires 100% of the Shanghai Transfusion Technology Co., LTD.Price Sensitive
-
Share buyback information
-
Share buyback information
-
Share buyback information
-
3F Buyback November 2021
-
Share buyback information
-
Share buyback information
-
Share buyback information
-
Notice of Publication of Documents
-
GVS Approves consolidated results to 30 September 2021Price Sensitive
-
Share buyback information
-
3F Buyback October 2021
-
Share buyback information
-
Share buyback information
-
Share buyback information
-
GVS Launches treasury share buyback programmePrice Sensitive
-
GVS Approves consolidated results to 30 June 2021 revenues up 29.7%, EBITDA margin at 37.9%Price Sensitive
-
GVS Acquires 100% of the RPB Group, an American player specialised in the design and production of respiratory protection devices, and completes its product range in the world of professional masksPrice Sensitive
-
GVS Approves consolidated results as at 31 March 2021Price Sensitive
-
The GVS BOD approves the 2020 financial statement: revenues up 60%, strong growth in Group profitability and solid increase in all key economic and financial indicatorsPrice Sensitive
-
2021 Corporate Events CalendarPrice Sensitive
-
GVS Approves the consolidated results at 30 September 2020 revenue up 49.6% and marked growth of the Group’s profit marginPrice Sensitive
-
The BOD of GVS approves the first half 2020 results revenue at 30 June 2020 up 25% and considerable growth in profit marginPrice Sensitive
-
Completion of the Closing of the acquisition of Haemonetics Puerto Rico, LLCPrice Sensitive
-
2020 Corporate Events CalendarPrice Sensitive
-
GVS Announces the agreement to acquire Puerto Rico-based manufacturing operations of Haemonetics
For the dissemination of Regulated Information, GVS SpA has chosen to use the eMarket SDIR system (www.emarketstorage.com), managed by Teleborsa S.r.l with headquarters in Roma, Piazza di Priscilla 4 and authorized by CONSOB.